(Reuters) - Alphabet Inc's
The search engine giant's life sciences division started the project in 2014 with Alcon, Novartis'
"Our clinical work on the glucose-sensing lens demonstrated that there was insufficient consistency in our measurements of the correlation between tear glucose and blood glucose concentrations to support the requirements of a medical device," Verily said https://blog.verily.com/2018/11/update-on-our-smart-lens-program-with.html.
(Reporting by Munsif Vengattil in Bengaluru; Editing by Maju Samuel)
This story has not been edited by Firstpost staff and is generated by auto-feed.
Firstpost is now on WhatsApp. For the latest analysis, commentary and news updates, sign up for our WhatsApp services. Just go to Firstpost.com/Whatsapp and hit the Subscribe button.
Updated Date: Nov 17, 2018 01:05:16 IST